The DEFINE AFib study is a prospective, observational, post-market clinical study. This nationwide, app-based study — sponsored by Medtronic — includes approximately 5,000 patients with a self-reported history of Aﬁb and either a Reveal LINQ™ or LINQ II™ insertable cardiac monitor (ICM).
We will use our research ﬁndings to improve the understanding of how data from the LINQ Family of ICMs can be used to guide the management of Aﬁb patients.
The study uses a combination of device data, electronic health records, and Apple® Health app data to evaluate the association between complex patterns of Afib and clinical outcomes and quality of life.
Eligible patients must meet the following criteria:
Additional criteria may apply.
By referring patients to the study, you will help us gather the crucial data needed to help us improve patient care. This data could help uncover insights that better guide the management of Aﬁb and help you improve your patients' outcomes now and in the future. In addition, physicians are compensated for their time spent recruiting patients.
We made it easy to enroll in the DEFINE AFib research study.
Start by downloading the Medtronic Discovery app from the Apple® App Store®, or click the link below.
Encourage your patients who meet the study criteria to download the Medtronic Discovery app and start the DEFINE AFib screening survey.
Medtronic takes care of the rest, making DEFINE AFib a low burden study for you and your practice.
Medtronic supports patients 24/7 through a help desk at 833-833-8321.
They’ll have special access to data from their Reveal LINQ or LINQ II device that shows their average Aﬁb duration.
Disclaimer: The display of device data on the app is not intended to be a substitute for medical diagnosis or treatment. The device data displayed on the app may not be reviewed by the healthcare provider.